Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IKT NYSE:PLX NYSE:PRME NASDAQ:VCKA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.90+2.2%$1.91$1.12▼$4.20$141.25M0.92279,088 shs232,497 shsPLXProtalix BioTherapeutics$1.50+4.9%$1.56$0.82▼$3.10$119.41M-0.23596,423 shs683,648 shsPRMEPrime Medicine$3.90-3.5%$2.13$1.11▼$6.62$524.53M2.331.77 million shs5.60 million shsVCKAVickers Vantage Corp. I$10.07$8.03▼$11.17$118.72M0.0336,105 shs1,404 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics+3.33%-7.92%-4.12%-1.85%+20.78%PLXProtalix BioTherapeutics+3.62%-6.54%0.00%-45.21%+22.22%PRMEPrime Medicine-5.83%-11.01%+169.33%+225.81%-39.70%VCKAVickers Vantage Corp. I0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIKTInhibikase Therapeutics1.2122 of 5 stars3.31.00.00.00.00.00.6PLXProtalix BioTherapeutics2.6504 of 5 stars3.53.00.00.01.40.01.9PRMEPrime Medicine3.8342 of 5 stars4.41.00.00.03.05.00.6VCKAVickers Vantage Corp. IN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics 2.50Moderate Buy$6.50242.11% UpsidePLXProtalix BioTherapeutics 3.00Buy$15.00900.00% UpsidePRMEPrime Medicine 2.75Moderate Buy$9.25137.18% UpsideVCKAVickers Vantage Corp. I 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VCKA, PRME, IKT, and PLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.005/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/APLXProtalix BioTherapeutics$59.76M2.00$0.08 per share17.80$0.47 per share3.19PRMEPrime Medicine$3.85M136.38N/AN/A$1.37 per share2.85VCKAVickers Vantage Corp. IN/AN/AN/A374.61($0.91) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/APLXProtalix BioTherapeutics$8.31M$0.04N/A4.84N/A-21.03%-30.89%-11.74%N/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/AVCKAVickers Vantage Corp. I$780KN/A0.00N/AN/AN/A-16.72%1.34%N/ALatest VCKA, PRME, IKT, and PLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4537.08%N/AN/A N/AVCKAVickers Vantage Corp. IN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A0.850.85PLXProtalix BioTherapeuticsN/A1.981.27PRMEPrime MedicineN/A6.506.50VCKAVickers Vantage Corp. IN/A0.201.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%PLXProtalix BioTherapeutics16.53%PRMEPrime Medicine70.37%VCKAVickers Vantage Corp. I84.46%Insider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics7.30%PLXProtalix BioTherapeutics6.50%PRMEPrime Medicine22.93%VCKAVickers Vantage Corp. I20.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionablePRMEPrime Medicine234134.50 million100.38 millionOptionableVCKAVickers Vantage Corp. IN/A13.18 million10.54 millionNot OptionableVCKA, PRME, IKT, and PLX HeadlinesRecent News About These CompaniesMurder charges against teen's mother droppedAugust 25, 2024 | bbc.comBRealty Income Corp ONovember 1, 2023 | morningstar.comMClover Corp.September 8, 2023 | forbes.comVickers Vantage Corp. I WarrantJuly 8, 2023 | thestreet.comKDKGF - Klondike Gold Corp.June 26, 2023 | finance.yahoo.comSelwyn M. VickersMarch 18, 2023 | statnews.comSSarah Kellen Vickers: 5 Fast Facts You Need to KnowMarch 17, 2023 | heavy.comHMiddleby Corp. reports sale increaseFebruary 23, 2023 | dailyherald.comD8-K: Lifevantage CorpFebruary 18, 2023 | marketwatch.comVickers Vantage Corp I (VCKAU)February 12, 2023 | investing.comKCI arises: Concessions manager aims to create 'extraordinary experience' for travelersJanuary 29, 2023 | bizjournals.comVantage Point providing a taste of EuropeJanuary 15, 2023 | bangkokpost.comBAdopt a pet in need through Vickers Animal RescueJanuary 15, 2023 | wjhg.comWIs Vickers Vantage Corp I (SCLX) Stock a Good Investment?November 15, 2022 | aaii.comAThe Funded: Shares of Palo Alto's Scilex up 12% since it hit Wall Street in the Bay Area's 14th SPAC merger of 2022November 15, 2022 | finance.yahoo.comShares of newly public biotech Scilex climb 5% following SPAC mergerNovember 11, 2022 | seekingalpha.comVickers Vantage Corp. I Ordinary Shares (VCKA)August 24, 2022 | nasdaq.comScilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement ...August 18, 2022 | bakersfield.comBVickers Vantage Corp. IAugust 16, 2022 | wsj.comSorrento's Scilex repurchases $41.4M notes ahead of going public with SPAC Vickers VantageJune 3, 2022 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCKA, PRME, IKT, and PLX Company DescriptionsInhibikase Therapeutics NYSE:IKT$1.90 +0.04 (+2.15%) Closing price 04:00 PM EasternExtended Trading$1.90 0.00 (-0.26%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Protalix BioTherapeutics NYSE:PLX$1.50 +0.07 (+4.90%) Closing price 04:00 PM EasternExtended Trading$1.50 +0.00 (+0.33%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Prime Medicine NYSE:PRME$3.90 -0.14 (-3.47%) Closing price 04:00 PM EasternExtended Trading$3.94 +0.04 (+0.90%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Vickers Vantage Corp. I NASDAQ:VCKAAs of November 10, 2022, Vickers Vantage Corp. I was acquired by Scilex Holding Company, in a reverse merger transaction. Vickers Vantage Corp. I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
